Aclaris Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los ingresos de Aclaris Therapeutics disminuyan a un ritmo anual de 3.1%, mientras que se prevé que sus beneficios anuales crezcan a un ritmo de 10.6% por año. Se espera que el BPA crezca en un 17.1% al año.
Información clave
10.6%
Tasa de crecimiento de los beneficios
17.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 27.6% |
| Tasa de crecimiento de los ingresos | -3.1% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 10 May 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow
Jun 08Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation
May 28Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -54 | -39 | -12 | 5 |
| 12/31/2025 | 11 | -50 | -48 | -11 | 9 |
| 12/31/2024 | 11 | -53 | -56 | -22 | 9 |
| 3/31/2024 | 31 | -77 | -74 | -73 | N/A |
| 12/31/2023 | 31 | -88 | -80 | -78 | N/A |
| 9/30/2023 | 21 | -115 | -92 | -91 | N/A |
| 6/30/2023 | 31 | -105 | -75 | -74 | N/A |
| 3/31/2023 | 31 | -96 | -74 | -73 | N/A |
| 12/31/2022 | 30 | -87 | -68 | -68 | N/A |
| 9/30/2022 | 24 | -82 | -66 | -66 | N/A |
| 6/30/2022 | 6 | -83 | -69 | -68 | N/A |
| 3/31/2022 | 6 | -81 | -61 | -61 | N/A |
| 12/31/2021 | 7 | -91 | -52 | -52 | N/A |
| 9/30/2021 | 7 | -82 | -44 | -44 | N/A |
| 6/30/2021 | 7 | -71 | -46 | -45 | N/A |
| 3/31/2021 | 7 | -65 | -44 | -44 | N/A |
| 12/31/2020 | 6 | -51 | -39 | -39 | N/A |
| 9/30/2020 | 6 | -57 | -51 | -50 | N/A |
| 6/30/2020 | 6 | -69 | -63 | -61 | N/A |
| 3/31/2020 | 4 | -102 | -73 | -72 | N/A |
| 12/31/2019 | 4 | -114 | -98 | -96 | N/A |
| 9/30/2019 | 5 | -118 | -105 | -103 | N/A |
| 6/30/2019 | 5 | -115 | -111 | -110 | N/A |
| 3/31/2019 | 6 | -79 | -112 | -110 | N/A |
| 12/31/2018 | 6 | -82 | -102 | -101 | N/A |
| 9/30/2018 | 5 | -81 | -94 | -92 | N/A |
| 6/30/2018 | 5 | -79 | -77 | -76 | N/A |
| 3/31/2018 | 3 | -86 | -65 | -64 | N/A |
| 12/31/2017 | 2 | -50 | N/A | -55 | N/A |
| 9/30/2017 | 1 | -57 | N/A | -45 | N/A |
| 6/30/2017 | N/A | -50 | N/A | -41 | N/A |
| 3/31/2017 | N/A | -48 | N/A | -40 | N/A |
| 12/31/2016 | N/A | -48 | N/A | -35 | N/A |
| 9/30/2016 | N/A | -42 | N/A | -31 | N/A |
| 6/30/2016 | N/A | -42 | N/A | -31 | N/A |
| 3/31/2016 | N/A | -33 | N/A | -24 | N/A |
| 12/31/2015 | N/A | -23 | N/A | -20 | N/A |
| 9/30/2015 | N/A | -21 | N/A | -19 | N/A |
| 6/30/2015 | N/A | -13 | N/A | -10 | N/A |
| 3/31/2015 | N/A | -12 | N/A | -9 | N/A |
| 12/31/2014 | N/A | -11 | N/A | -8 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que ACRS siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que ACRS siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que ACRS siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos de ACRS disminuyan en los próximos 3 años (-3.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos de ACRS disminuyan en los próximos 3 años (-3.1% al año).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ACRS se prevé que sea elevada dentro de 3 años.